New Portal Vein Thrombosis in Cirrhosis - is the Thrombophilia Exacerbated due to Vaccine or COVID-19?

Premkumar, Madhumita; Bhujade, Harish; Karki, Tanka; Chaluvashetty, Sreedhara B; Kaur, Harmanpreet; Duseja, Ajay; Singh, Virendra

doi:10.1016/j.jceh.2021.10.149

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous discussion around COVID-19 vaccination has raised the question of whether or not vaccines to COVID-19 confer upon patients a hypercoagulable state [105][106][107]. We reviewed 4 reports (5 patients, 6 eyes) commenting on vascular events following COVID-19 vaccination.…”

Section: Vascularmentioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

Vaccination efforts as a mitigation strategy in the corona virus disease 2019 (COVID-19) pandemic are fully underway. A vital component of understanding the optimal clinical use of these vaccines is a thorough investigation of adverse events following vaccination. To date, some limited reports and reviews have discussed ocular adverse events following COVID-19 vaccination, but a systematic review detailing these reports with manifestations and clinical courses as well as proposed mechanisms has yet to be published. This comprehensive review one-year into vaccination efforts against COVID-19 is meant to furnish sound understanding for ophthalmologists and primary care physicians based on the existing body of clinical data. We discuss manifestations categorized into one of the following: eyelid, orbit, uveitis, retina, vascular, neuro-ophthalmology, ocular motility disorders, and other.

show abstract

Section: Vascularmentioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fourteen PVT patients were donors after brain death (n = 14, 27.4%) [95,109] and seven patients had no medical history (n = 7, 13.7%) [4,5,52,64,66], however, some of the patients had a past drug history of regular intake of oral contraceptive pills (n = 6, 11.5%) [31,51,53,54,64,111,116]. Few PVT patients had preexisting diabetes mellitus (n = 3) [56,59,67], migraine (n = 3) [51,65,111], thyroid gland disorders [hypothyroidism and goiter] (n = 4), and obesity (n = 3) [61,63,116]. Nevertheless, medical history was not reported for five PVT cases [3,30,62,91,98] [3-5, 49, 51-59, 61, 63, 65, 66, 76, 96, 111, 116] and few PVT patients were in a coma (n = 3, 5.9%) [64].…”

Section: Portal Vein Thrombosismentioning

confidence: 99%

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

et al. 2022

View full text Add to dashboard Cite

Background Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. Objectives To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. Methods For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. Results Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. Conclusion Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.

show abstract

“…Among patients with prior VTE, it has been shown that there was actually a lower risk for VTE after vaccination 3 . In the background of VITT, potentially coincidental VTE events occurring after vaccination have been analyzed with increased scrutiny and even after large studies demonstrated no generalized increase in VTE risk, published case reports continue to question the safety in those with thrombophilia 6–9 with calls for definitive research in this area 10 …”

Section: Introductionmentioning

confidence: 99%

“…Among patients with prior VTE, it has been shown that there was actually a lower risk for VTE after vaccination. 3 In the background of VITT, potentially coincidental VTE events occurring after vaccination have been analyzed with increased scrutiny and even after large studies demonstrated no generalized increase in VTE risk, published case reports continue to question the safety in those with thrombophilia [6][7][8][9] with calls for definitive research in this area. 10 Patients with inherited or acquired thrombophilia remain concerned about their thrombotic risk with COVID-19 vaccination due to their unique circumstances, with some avoiding vaccination due to personal concerns or in some cases medical advice.…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia

et al. 2023

View full text Add to dashboard Cite

Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 vaccinations. The aim of this study was to examine VTE outcomes in patients with inherited or acquired thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE occurring 90 days before and after the date of the first vaccine dose. Thrombophilia patients

show abstract

New Portal Vein Thrombosis in Cirrhosis - is the Thrombophilia Exacerbated due to Vaccine or COVID-19?

Cited by 7 publications

References 7 publications

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

Venous thromboembolism after COVID‐19 vaccination in patients with thrombophilia

Contact Info

Product

Resources

About